$HELP

Glavine Paul purchased $1.2M of HELP

Glavine Paul (Chief Growth Officer) purchased 100,000 shares of CYBIN INC. (HELP) at $11.78 ($1.18M total) on 2026-09-03.

Original reporting
SEC EDGAR · Glavine Paul
Published Sep 10, 2026, 10:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 10:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HELP
Bullish
medium confidence
Mentioned
$HELP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HELPBullishMed
01

Why it matters

The purchase adds to insider confidence metrics and may influence short‑term trading decisions.

02

Market read

Insider purchase of a micro‑cap biotech can prompt short‑term price movement.

03

What to watch

Potential upcoming clinical trial data or partnership announcements not disclosed yet.

Relevance 7/10Novelty 6/10Timing: post-market filing

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$HELPBullishMedium confidence
Context

Chief Growth Officer Glavine Paul bought 100,000 shares of Cybin Inc. for $1.18M, increasing his stake to over 4 million shares.

Expected impact

Potential modest price uptick as market views the buy as a bullish signal.

Evidence & confidence

The purchase size is notable for a micro‑cap biotech and the insider holds a senior growth role, suggesting belief in upcoming catalysts.

Market effects

May lift sentiment in the biotech sector as insider buying is viewed positively.

Limited to US biotech investors.

Low global impact.

Counterpoint

Insider buying could be a routine portfolio rebalancing, not a catalyst.

Key entities

  • Cybin Inc.

    US‑listed biotech (ticker HELP).

  • Glavine Paul

    Chief Growth Officer of Cybin Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HELPMed

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma (Nasdaq: HELP) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Cash was $166.4M. Net loss was $47.8M vs $24.6M a year earlier. The company said Phase 3 APPROACH enrollment for HLP003 in MDD is complete with topline data expected in Q4 2026, and a DDI study showed no meaningful PK interaction. It also completed a $50M underwritten offering in June 2026.

$HELPMed

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.